Dermata Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.7M
- Price
- $1.42
- % Change (Daily % change from the live per-ticker quote feed.)
- -9.55%
- Volume
- 421.6K
About
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Quick stats
Shares outstanding4.0M
Computed float3.1M
Float / shares77.8%
Cash runway (months)6.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001853816
Websitehttps://www.dermatarx.com
AI Summary
AI-generated1/11
majormixedearnings
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
Dermata set August 25, 2026, as the launch date for its first commercial product, the Tome Foundational Treatment, marking its transition to a direct-to-consumer skincare model.
Financial results for the second quarter showed cash decreased to $4.4 million from $7.5 million at year-end, with operations consuming $4.9 million over the past six months.
Management stated that current cash resources are sufficient to fund operations only into the fourth quarter of 2026, highlighting an urgent need for immediate revenue or further capital raises.
Red flags
- Cash runway extends only into Q4 2026
- Net loss of $2.97M for the quarter
- Increased legal fees of $0.7M contributed to higher SG&A